Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).
Meertens M, Muntinghe-Wagenaar MB, Sikkema BJ, Lopez-Yurda M, Retèl VP, Paats MS, Ter Heine R, Schuuring E, Timens W, Touw DJ, van Boven JFM, de Langen AJ, Hashemi SMS, Hendriks LEL, Croes S, van den Heuvel MM, Dingemans AC, Mathijssen RHJ, Smit EF, Huitema ADR, Steeghs N, van der Wekken AJ. Meertens M, et al. Among authors: muntinghe wagenaar mb. Front Oncol. 2023 Mar 9;13:1136221. doi: 10.3389/fonc.2023.1136221. eCollection 2023. Front Oncol. 2023. PMID: 36969063 Free PMC article.
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.
Kievit H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, Slingers G, de Vries R, Groen HJM, Kerstjens HAM, van der Wekken AJ, Hiltermann TJN. Kievit H, et al. Among authors: muntinghe wagenaar mb. Lung Cancer. 2023 Apr;178:96-102. doi: 10.1016/j.lungcan.2023.02.004. Epub 2023 Feb 7. Lung Cancer. 2023. PMID: 36806899 Free article. Clinical Trial.
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Zwierenga F, Muntinghe-Wagenaar MB, Rozendal P, de Langen AJ, Hendriks LEL, van den Heuvel M, van der Leest C, Hashemi SMS, van der Leest P, Hiltermann TJN, Schuuring E, van der Wekken AJ. Zwierenga F, et al. Among authors: muntinghe wagenaar mb. Target Oncol. 2025 Jun 5. doi: 10.1007/s11523-025-01153-5. Online ahead of print. Target Oncol. 2025. PMID: 40473885
Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study" by Liu et al., G. Rocco, and Szarpak et al.
Buma AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, Schuurbiers MMF, Sterk PJ, Schipper SPM, Meurs J, Cristescu SM, Hiltermann TJN, van den Heuvel MM. Buma AIG, et al. Among authors: muntinghe wagenaar mb. Ann Oncol. 2025 Jul;36(7):842-844. doi: 10.1016/j.annonc.2025.05.006. Epub 2025 Jun 2. Ann Oncol. 2025. PMID: 40461382 No abstract available.
Lung cancer detection by electronic nose analysis of exhaled breath: a multicentre prospective external validation study.
Buma AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, Schuurbiers MMF, Sterk PJ, Schipper SPM, Meurs J, Cristescu SM, Hiltermann TJN, van den Heuvel MM. Buma AIG, et al. Among authors: muntinghe wagenaar mb. Ann Oncol. 2025 Jul;36(7):786-795. doi: 10.1016/j.annonc.2025.03.013. Epub 2025 Mar 31. Ann Oncol. 2025. PMID: 40174676 Free article.
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.
Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, Ulas EB, Trooster TMA, de Jonge E, Oomen-de Hoop E, Paats MS, Bahce I, Croes S, Hendriks LEL, van der Wekken AJ, Dingemans AC, Huitema ADR, van Schaik RHN, Mathijssen RHJ, Veerman GDM. Heersche N, et al. Among authors: muntinghe wagenaar mb. J Thorac Oncol. 2025 Apr;20(4):475-486. doi: 10.1016/j.jtho.2024.11.025. Epub 2024 Nov 29. J Thorac Oncol. 2025. PMID: 39617342 Free article.
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.
Kievit H, Muntinghe-Wagenaar MB, Abdulahad WH, Rutgers A, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, van der Leij MJ, Bijzet J, Groen HJM, Kerstjens HAM, van der Wekken AJ, Kroesen BJ, Hiltermann TJN. Kievit H, et al. Among authors: muntinghe wagenaar mb. Cancers (Basel). 2024 Jul 19;16(14):2592. doi: 10.3390/cancers16142592. Cancers (Basel). 2024. PMID: 39061230 Free PMC article.